<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433107</url>
  </required_header>
  <id_info>
    <org_study_id>727-D-301</org_study_id>
    <nct_id>NCT01433107</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of Terbinafine Film Forming Solution, 1% (as Hydrochloride), in Patients With Tinea Pedis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the efficacy and safety of a single dose of terbinafine film forming
      solution 1% with a single dose of placebo film forming solution in the treatment of tinea
      pedis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2)</measure>
    <time_frame>week 6</time_frame>
    <description>Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale:
0 = absent
= mild
= moderate
= severe In order to calculate the total symptoms score the rating for all symptoms are added up.
Possible range 0 to 18</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Clinical Signs and Symptoms (S/S) Scores</measure>
    <time_frame>week 6</time_frame>
    <description>Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale:
0 = absent
= mild
= moderate
= severe In order to calculate the total symptom score, the scores for each individual symptom are added up.
Possible range : 0 to 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Event</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of Subjects with adverse event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Terbinafine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine</intervention_name>
    <description>1% single application</description>
    <arm_group_label>Terbinafine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine Placebo</intervention_name>
    <description>single application</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 years of age with interdigital tinea pedis infection, with clinical
             diagnosis meeting required baseline total sign &amp; symptom score and positive microscopy

        Exclusion Criteria:

          -  Allergy to the allylamine class of antimycotics or excipients in the formulation.

          -  Chronic, hyperkeratotic plantar (moccasin) tinea pedis

          -  Other fungal disease or intertrigo

          -  Other abnormal findings on the affected foot

          -  Systemic antifungal or antimicrobial treatment within the last 3 months

          -  Topical treatment for skin lesions on feet within the last 3 months

          -  Diabetes mellitus and peripheral artery occlusive disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing University Hospital N°3</name>
      <address>
        <city>Beijing</city>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Sun Yat-sen University Guangzhou</name>
      <address>
        <city>Guangdong</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences</name>
      <address>
        <city>Jiangsu</city>
        <zip>21004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2011</study_first_posted>
  <results_first_submitted>April 8, 2013</results_first_submitted>
  <results_first_submitted_qc>December 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 27, 2013</results_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tinea pedis</keyword>
  <keyword>Terbinafine film forming solution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study start 27 Aug 2011 end 14 Feb 2012</recruitment_details>
      <pre_assignment_details>Each particiapant received a single dose of Terbinafine Film Forming Solution 1% or matching placebo</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Terbinafine</title>
          <description>Drug</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Terbinafine</title>
          <description>Drug</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Drug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="145"/>
            <count group_id="B2" value="145"/>
            <count group_id="B3" value="290"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.27" spread="12.805"/>
                    <measurement group_id="B2" value="34.05" spread="11.936"/>
                    <measurement group_id="B3" value="34.66" spread="12.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2)</title>
        <description>Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale:
0 = absent
= mild
= moderate
= severe In order to calculate the total symptoms score the rating for all symptoms are added up.
Possible range 0 to 18</description>
        <time_frame>week 6</time_frame>
        <population>Number of success. The discrepancy between number of participants analyzed and participants completed is explained by delayed exclusions (people having negative mycology results received after completion of the study).</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine</title>
            <description>Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2)</title>
          <description>Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale:
0 = absent
= mild
= moderate
= severe In order to calculate the total symptoms score the rating for all symptoms are added up.
Possible range 0 to 18</description>
          <population>Number of success. The discrepancy between number of participants analyzed and participants completed is explained by delayed exclusions (people having negative mycology results received after completion of the study).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Clinical Signs and Symptoms (S/S) Scores</title>
        <description>Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale:
0 = absent
= mild
= moderate
= severe In order to calculate the total symptom score, the scores for each individual symptom are added up.
Possible range : 0 to 18</description>
        <time_frame>week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine</title>
            <description>Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug</description>
          </group>
        </group_list>
        <measure>
          <title>Total Clinical Signs and Symptoms (S/S) Scores</title>
          <description>Each clinical sign or symptom will be assessed separately. The investigator will evaluate the severity of each sign or symptom over the entire target foot. Clinical signs and symptoms including desquamation (scaling), erythema, incrustation (crusting), pustules, vesiculation and pruritus will be evaluated by the investigator or designee and recorded at every visit using the following scale:
0 = absent
= mild
= moderate
= severe In order to calculate the total symptom score, the scores for each individual symptom are added up.
Possible range : 0 to 18</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.3" upper_limit="2.0"/>
                    <measurement group_id="O2" value="4.7" lower_limit="4.1" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Event</title>
        <description>Number of Subjects with adverse event</description>
        <time_frame>6 weeks</time_frame>
        <population>Number of subject with any adverse events mild or moderate having signed the informed consent. One subject had an adverse event but did not receive any study drug and was not included in the number of subjects started.</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine</title>
            <description>Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Event</title>
          <description>Number of Subjects with adverse event</description>
          <population>Number of subject with any adverse events mild or moderate having signed the informed consent. One subject had an adverse event but did not receive any study drug and was not included in the number of subjects started.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>One subject had an adverse event but did not receive any study drug and was not included in the number of subjects started.</desc>
      <group_list>
        <group group_id="E1">
          <title>Terbinafine</title>
          <description>Drug</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Drug</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Preliminary agreement between Novartis Consumer Health and the investigator</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Project leader</name_or_title>
      <organization>Novartis</organization>
      <phone>+41223633111</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

